Cardiovascular diseases (CVDs) are among the most impactful illnesses globally. Currently, the available therapeutic option has several side effects, including hypotension, bradycardia, arrhythmia, and alteration in different ion concentrations. Recently, bioactive compounds from natural sources, including plants, microorganisms, and marine creatures, have gained a lot of interest. Marine sources serve as reservoirs for new bioactive metabolites with various pharmacological activities. The marine-derived compound such as omega-3 acid ethyl esters, xyloketal B, asperlin, and saringosterol showed promising results in several CVDs. The present review focuses on marine-derived compounds’ cardioprotective potential for hypertension, ischemic heart disease, myocardial infarction, and atherosclerosis. In addition to therapeutic alternatives, the current use of marine-derived components, the future trajectory, and restrictions are also reviewed.

Parkinson’s disease (PD) is a prevalent neurological illness that manifests itself sporadically. The destruction of dopaminergic neuronal cells in the substantia nigra is the primary cause of PD. The cause of PD is unknown, while its pathogenesis is becoming to be recognized as a complex cascade of harmful elements. The majority of insights regarding PD pathogenesis reported evidence of experimental PD models, particularly those caused by neurotoxins. Although many natural and synthetic chemicals have negative effects on neuronal cells of the dopaminergic region, only a few are employed in living animal studies to mimic some of the symptoms of PD. Therefore, more studies are required to better understand the causes of PD and select better neurotoxin models in animals. In this review, we discussed the treatment drugs and animal induced model (neurotoxin model) including MPTP, rotenone,6-hydroxydopamine (6-OHDA), manganese, and paraquat for Parkinson’s disease. We also discussed the neuropathological disease stages and telemedicine current status for PD.